Achieving SVR in patients with hepatitis C-related HCC is associated with an improvement in overall survival: real word data

Abstract

Aims: The optimal timing for DAA therapy initiation in patients with chronic hepatitis C (CHC) and HCC is still debated. The aim of our study was to provide real-world data on virological response and overall survival in patients with hepatitis C-related HCC.

Methods: Retrospectively, we included patients with HCV-related HCC between 2015 and 2020. The primary outcome was to compare the SVR rate in the patients with active or historical HCC who were treated with DAA therapy. The secondary outcome was to measure the overall survival of those patients.

Results: 98 patients were included, and the majority were cirrhotic with compensated liver disease. 71.4% received DAA therapy at the time of initial HCC diagnosis and 11.2% received HCV treatment at the time of HCC recurrence (Active HCC cohort). 17.3% had previously received HCC treatment, but there was no evidence of recurrence at the time of DAA (Historical HCC Cohort). The SVR rate was 81.6%, but decreased to 75.7% in patients with active HCC. The presence of active HCC and the number of HCC nodules were the only factors associated with not achieving SVR in the multivariate analysis. The median survival was higher in those who achieved SVR. Active HCC and failure to achieve SVR were the main factors associated with mortality.

Conclusions: Treating hepatitis C in patients with HCC is feasible with significant rates of SVR, even if SVR rates decrease in patients with active HCC and these patients require more than one DAA therapy. Failure to achieve SVR is one of the main factors associated with mortality.

Keywords

Hepatitis C treatment / hepatocellular carcinoma / DAA therapy / sustained virological response / overall survival

References

[1] Bray F,Soerjomataram I,Torre LA.Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2018;68:394-424

[2] Ioannou GN,Green PK.Increased risk for hepatocellular carcinoma persists up to 10 years after HCV eradication in patients with baseline cirrhosis or high FIB-4 scores.Gastroenterology2019;157:1264-78.e4 PMCID:PMC6815714

[3] Alavi M,Valerio H.Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.J Hepatol2019;71:281-8

[4] Rodríguez-Tajes S,Castillo J.Hepatitis C-related cirrhosis will be a marginal cause of hospital admissions by 2025.J Hepatol2020;73:1360-7

[5] Pascasio JM,Ferrer MT.Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation.J Hepatol2017;67:1168-76

[6] Perricone G,Berenguer M.European Liver and Intestine Transplant Association (ELITA)Delisting HCV-infected liver transplant candidates who improved after viral eradication: outcome 2 years after delisting.Liver Int2018;38:2170-7

[7] Reig M,Perelló C.Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy.J Hepatol2016;65:719-26

[8] Saraiya N,Rich NE,Parikh ND.Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy.Aliment Pharmacol Ther2018;48:127-37 PMCID:PMC6019180

[9] Frazzoni L,Metelli F.Hepatocellular carcinoma recurrence after hepatitis C virus therapy with direct-acting antivirals. A systematic review and meta-analysis.J Clin Med2021;10:1694 PMCID:PMC8071154

[10] Singal AG,Kanwal F.AGA clinical practice update on interaction between oral direct-acting antivirals for chronic hepatitis C infection and hepatocellular carcinoma: expert review.Gastroenterology2019;156:2149-57 PMCID:PMC6529246

[11] Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma.J Hepatol2018;69:182-236

[12] Reig M,Rimola J.BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update.J Hepatol2022;76:681-93 PMCID:PMC8866082

[13] He S,Alavi M,Hajarizadeh B.Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma.Aliment Pharmacol Ther2020;51:34-52

[14] Ogawa E,Iio E.Real-World Evidence from the Asia Liver Consortium InvestigatorsHepatitis C virus cure rates are reduced in patients with active but not inactive hepatocellular carcinoma: a practice implication.Clin Infect Dis2020;71:2840-8

[15] Ji F,Wei MT.Sustained virologic response to direct-acting antiviral therapy in patients with chronic hepatitis C and hepatocellular carcinoma: a systematic review and meta-analysis.J Hepatol2019;71:473-85

[16] Huang CF.Direct-acting antivirals response in hepatocellular carcinoma: Does the presence of hepatocellular carcinoma matter?.Clin Mol Hepatol2019;25:168-71 PMCID:PMC6589855

[17] Cabibbo G,Calvaruso V.Rete Sicilia Selezione Terapia - HCV (RESIST-HCV) and Italian Liver Cancer (ITALI.CA.) Group. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.J Hepatol2019;71:265-73

[18] Kuromatsu R,Okamura S.Hepatitis C virus elimination using direct acting antivirals after the radical cure of hepatocellular carcinoma suppresses the recurrence of the cancer.Cancers2022;14:2295 PMCID:PMC9103530

[19] Parikh ND,Hoteit MA.Association between sustained virological response and clinical outcomes in patients with hepatitis C infection and hepatocellular carcinoma.Cancer2022;128:3470-8 PMCID:PMC9545187

[20] Cabibbo G,Barbara M.Italian Liver Cancer (ITALI.CA) group. Hepatic decompensation is the major driver of death in HCV-infected cirrhotic patients with successfully treated early hepatocellular carcinoma.J Hepatol2017;67:65-71